儿童及青少年原发性血小板增多症与纤维化前原发性骨髓纤维化:来自中国大型队列的诊断、结局与治疗见解
该研究分析中国双向队列中儿童及青少年原发性血小板增多症(CAA-ET,n=156)、纤维化前原发性骨髓纤维化(CAA-preMF,n=13)及成人ET(n=349),引入免疫表型异常作为新的克隆标志,发现CAA-ET与成人ET突变谱不同,JAK2 V617F与静脉血栓相关(P=0.018),免疫表型异常为疾病进展危险因素(P=0.027),CAA-preMF无进展生存较CAA-ET更差(P<0.001)。
要点
- JAK2 V617F是CAA-ET静脉血栓的潜在危险因素(P=0.018)。
- 免疫表型异常是CAA-ET和CAA-preMF疾病进展的危险因素(P=0.027)。
- CAA-preMF较CAA-ET无进展生存更差(P<0.001)、疾病进展更快(P=0.019)。
核心结论
- 本研究为完善CAA-ET和CAA-preMF的诊断、预后和治疗策略提供了重要基础。
研究设计与样本
- 研究分析了一个大型双向队列,包括儿童及青少年ET(CAA-ET,n=156)、pre-PMF(CAA-preMF,n=13)以及成人ET(n=349)。
- 研究引入免疫表型异常作为CAA-ET和CAA-preMF的新型克隆标志,建立了整合驱动与非驱动突变、内源性红系集落形成阳性、免疫表型异常及染色体畸变的综合克隆标志检测方法。
主要发现
- 二代测序显示CAA-ET与成人ET之间突变谱不同,驱动突变分布随年龄变化趋势也不同。
- 静脉血栓在CAA-ET中更常见,JAK2 V617F是潜在危险因素(P=0.018)。
- 免疫表型异常被确定为疾病进展的危险因素(P=0.027)。
- 预期治疗实践与实际治疗实践之间存在显著差异。
- 与CAA-ET相比,CAA-preMF无进展生存更差(P<0.001),疾病进展更快(P=0.019)。
关键数值与推荐
- CAA-ET中JAK2 V617F与静脉血栓风险的关联P=0.018。
- 免疫表型异常与疾病进展风险的关联P=0.027。
- CAA-preMF与CAA-ET无进展生存差异P<0.001。
- CAA-preMF与CAA-ET疾病进展速度差异P=0.019。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The paucity of essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) in individuals younger than 18 years highlights several unresolved issues in diagnosis, clinical outcomes, and treatment strategies. To address these knowledge gaps, we analyzed a large bidirectional cohort consisting of childhood and adolescent ET (CAA-ET, n = 156) and pre-PMF (CAA-preMF, n = 13), as well as adult ET (n = 349). We introduced immunophenotypic abnormalities as novel clonal markers in CAA-ET and CAA-preMF, establishing a comprehensive method for clonal marker detection that integrated driver and non-driver mutations, positive endogenous erythroid colony formation, immunophenotypic abnormalities, and chromosomal aberrations. Next-generation sequencing revealed distinct mutational profiles between CAA-ET and adult ET, along with different age-related trends in the distribution of driver mutations. Venous thrombosis was more prevalent in CAA-ET, with JAK2 V617F emerging as a potential risk factor (P = 0.018). Immunophenotypic abnormalities were identified as risk factors for disease progression (P = 0.027). Significant differences between expected and actual treatment practices were identified. Compared to CAA-ET, CAA-preMF demonstrated poorer progression-free survival (P < 0.001) and faster disease progression (P = 0.019). This study provides a critical foundation for refining diagnostic, prognostic, and therapeutic approaches for CAA-ET and CAA-preMF.
引用
- Fu R, Dong H, Gu W, et al. Childhood and adolescent essential thrombocythemia and prefibrotic primary myelofibrosis: insights into diagnosis, outcomes, and treatment from a large Chinese cohort. Leukemia. 2024. PMID: 39375514. doi:10.1038/s41375-024-02432-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。